| PXS Pharmaxis Commences Phase 1 LOX Clinical Trial |
| 22/02/19 | PRICE SENSITIVE | | Share |
|
| PXS Half Yearly Report and Accounts |
| 14/02/19 | PRICE SENSITIVE | | Share |
|
| PXS Quarterly Shareholder Update - December 2018 |
| 30/01/19 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 30/01/19 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Announces LOXL2 Program Phase 2 Ready |
| 17/01/19 | PRICE SENSITIVE | | Share |
|
| PXS PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USA |
| 20/12/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Announces First Relaunch Sales of Aridol in USA |
| 13/12/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis AGM - CEO Presentation |
| 22/11/18 | PRICE SENSITIVE | | Share |
|
| PXS Chairman's Address to Shareholders |
| 22/11/18 | PRICE SENSITIVE | | Share |
|
| PXS LOX Inhibitor Program for Pancreatic Cancer Phase 1 Ready |
| 20/11/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Releases Positive Results of Phase 1 Clinical Tria |
| 15/11/18 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 26/10/18 | PRICE SENSITIVE | | Share |
|
| PXS Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor |
| 11/10/18 | PRICE SENSITIVE | | Share |
|
| PXS Preliminary Final Report |
| 17/08/18 | PRICE SENSITIVE | | Share |
|
| PXS FDA Factory Approval and Relaunch of Aridol in US Market |
| 15/08/18 | PRICE SENSITIVE | | Share |
|
| PXS Capital Raising Presentation |
| 06/08/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Announces A$24m Placement |
| 06/08/18 | PRICE SENSITIVE | | Share |
|
| PXS Trading Halt Announcement - System Upgrade |
| 06/08/18 | PRICE SENSITIVE | | Share |
|
| PXS Trading Halt |
| 03/08/18 | PRICE SENSITIVE | | Share |
|
| PXS Quarterly Shareholder Update - June 2018 |
| 27/07/18 | PRICE SENSITIVE | 441.24KB | Share |
|
| PXS Appendix 4C - quarterly |
| 27/07/18 | PRICE SENSITIVE | 122.6KB | Share |
|
| PXS LOXL2 Program Attracts Strong Partner Interest at BIO18 |
| 14/06/18 | PRICE SENSITIVE | 120.63KB | Share |
|
| PXS Quarterly Shareholder Update - March 2018 |
| 30/04/18 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 30/04/18 | PRICE SENSITIVE | | Share |
|
| PXS Half Yearly Report and Accounts |
| 15/02/18 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 29/01/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Earns A$15 Million Milestone Payment |
| 11/01/18 | PRICE SENSITIVE | | Share |
|
| PXS New Australian PBS Listing for Brocnhitol |
| 02/01/18 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Acquires Control, Increases Stake in LOXL2 Program |
| 14/12/17 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 27/10/17 | PRICE SENSITIVE | | Share |
|
| PXS Boehringer Initiating Phase 2a Study Diabetic Retinopathy |
| 08/09/17 | PRICE SENSITIVE | | Share |
|
| PXS Antifibrotic LOXL2 Program Clears Preclinical Development |
| 06/09/17 | PRICE SENSITIVE | | Share |
|
| PXS Boehringer Ingelheim Initiates Phase IIa Study in NASH |
| 25/08/17 | PRICE SENSITIVE | | Share |
|
| PXS Positive Recommendation for Broader Bronchitol Access in Aus |
| 18/08/17 | PRICE SENSITIVE | | Share |
|
| PXS Preliminary Final Report June 2017 |
| 11/08/17 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly June 2017 |
| 28/07/17 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Announces Results of Pivotal CF Clinical Trial |
| 13/06/17 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Set to Generate Further Euro 10m Milestone Payment |
| 15/05/17 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Appoints Chiesi as Bronchitol Distributor in Italy |
| 08/05/17 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly cash flow |
| 18/04/17 | PRICE SENSITIVE | | Share |
|
| PXS Quarterly Shareholder Update March 2017 |
| 18/04/17 | PRICE SENSITIVE | | Share |
|
| PXS Synairgen Collaboration Progress |
| 13/03/17 | PRICE SENSITIVE | | Share |
|
| PXS Half Yearly Report and Accounts |
| 17/02/17 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 30/01/17 | PRICE SENSITIVE | | Share |
|
| PXS Chairman's Address to Shareholders |
| 29/11/16 | PRICE SENSITIVE | | Share |
|
| PXS Research Collaboration with Woolcock Institute |
| 15/11/16 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly-PXS.AX |
| 28/10/16 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Announces Russian Approval for Bronchitol-PXS.AX |
| 27/09/16 | PRICE SENSITIVE | | Share |
|
| PXS Preliminary Final Report-PXS.AX |
| 19/08/16 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly-PXS.AX |
| 29/07/16 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Completes Recruitment of CF Clinical Trial for US-PXS.AX |
| 15/07/16 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly March 2016-PXS.AX |
| 14/04/16 | PRICE SENSITIVE | | Share |
|
| PXS Synairgen Collaboration Progress |
| 23/03/16 | PRICE SENSITIVE | | Share |
|
| PXS Half Yearly Report and Accounts |
| 26/02/16 | PRICE SENSITIVE | | Share |
|
| PXS Quarterly Share Update - December 2015 |
| 29/01/16 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 29/01/16 | PRICE SENSITIVE | | Share |
|
| PXS Bronchitol Paediatric CF Trial Reports Postive Results |
| 16/12/15 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 23/10/15 | PRICE SENSITIVE | | Share |
|
| PXS PXS Releases Successful Phase Results of Phase 1 Trial |
| 22/09/15 | PRICE SENSITIVE | | Share |
|
| PXS Preliminary Final Report |
| 19/08/15 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis and Synairgen Announce Research Collaboration |
| 05/08/15 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 31/07/15 | PRICE SENSITIVE | | Share |
|
| PXS PXS Announces Completion of Restructuring and New Focus |
| 19/05/15 | PRICE SENSITIVE | | Share |
|
| PXS Boehringer Ingelheim acquires Pharmaxis phase 1 drug |
| 18/05/15 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Signs Second Agreement with Chiesi |
| 08/05/15 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly cash flow |
| 17/04/15 | PRICE SENSITIVE | | Share |
|
| PXS Interim Results of Phase 1 Clinical Trial for PXS4728A |
| 07/04/15 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Signs with Boehringer Ingelheim for PXS4728A |
| 12/03/15 | PRICE SENSITIVE | | Share |
|
| PXS Half Yearly Report and Accounts |
| 26/02/15 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 30/01/15 | PRICE SENSITIVE | | Share |
|
| PXS Commencement of Phase 1 Clinical Trial for SSAO Inhibitor |
| 21/01/15 | PRICE SENSITIVE | | Share |
|
| PXS Commercialisation in US and NovaQuest Dispute Settled |
| 24/12/14 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 30/10/14 | PRICE SENSITIVE | | Share |
|
| PXS Phase 3 Clinical Trial in Cystic Fibrosis |
| 30/10/14 | PRICE SENSITIVE | | Share |
|
| PXS New data from B305 clinical trial presented at ERS |
| 08/09/14 | PRICE SENSITIVE | | Share |
|
| PXS Preliminary Final Report, Financial and Directors' Report |
| 28/08/14 | PRICE SENSITIVE | | Share |
|
| PXS SSAO Inhibitor Ready for the Clinic |
| 28/08/14 | PRICE SENSITIVE | | Share |
|
| PXS Pharmaxis Files Lawsuit Against NovaQuest |
| 04/08/14 | PRICE SENSITIVE | | Share |
|
| PXS Appendix 4C - quarterly |
| 30/07/14 | PRICE SENSITIVE | | Share |
|
| PXS Update On Timing Of Pre-Clinical Partnering Projects |
| 08/07/14 | PRICE SENSITIVE | | Share |
|
| PXS Communication from Financier NovaQuest |
| 08/07/14 | PRICE SENSITIVE | | Share |
|
| PXS Trading Halt |
| 04/07/14 | PRICE SENSITIVE | | Share |
|
| PXSAppendix 4C - quarterly |
| 16/04/14 | PRICE SENSITIVE | | Share |
|
| PXSHalf Yearly Report and Accounts |
| 19/02/14 | PRICE SENSITIVE | | Share |
|
| PXSAppendix 4C - quarterly |
| 30/01/14 | PRICE SENSITIVE | | Share |
|
| PXSScottish Medicines Consortium Accepts Bronchitol for CF Use |
| 10/12/13 | PRICE SENSITIVE | | Share |
|
| PXSPharmaxis Elects to Receive Full NovaQuest Investment |
| 30/10/13 | PRICE SENSITIVE | | Share |
|
| PXSAppendix 4C - quarterly |
| 16/10/13 | PRICE SENSITIVE | | Share |
|
| PXSPharmaxis Announces Delay to French Pricing for Bronchitol |
| 29/08/13 | PRICE SENSITIVE | | Share |
|
| PXSPreliminary Final Report |
| 15/08/13 | PRICE SENSITIVE | | Share |
|
| PXSPHARMAXIS ANNOUNCES IMPROVED PBS LISTING OF BRONCHITOL |
| 18/07/13 | PRICE SENSITIVE | | Share |
|
| PXSAppendix 4C - quarterly |
| 17/07/13 | PRICE SENSITIVE | | Share |
|
| PXSPharmaxis Awarded Two ARC Linkage Grants |
| 05/07/13 | PRICE SENSITIVE | | Share |
|
| PXSEuropean CF Clinical Trial in Paediatric Patients Begins |
| 20/06/13 | PRICE SENSITIVE | | Share |
|
| PXSPharmaxis Presents New Analyses of Pooled CF Data at EU Meet |
| 18/06/13 | PRICE SENSITIVE | | Share |
|
| PXSAridol FDA Import Restrictions |
| 03/06/13 | PRICE SENSITIVE | | Share |
|
| PXSOutcome of Business Review |
| 28/05/13 | PRICE SENSITIVE | | Share |
|
| PXSPharmaxis Appoints Bronchitol Distributor for Poland |
| 22/05/13 | PRICE SENSITIVE | | Share |
|
| PXSFDA Meeting, Business Review Announcement End of May |
| 14/05/13 | PRICE SENSITIVE | | Share |
|
| PXSPHASE 3 CLINICAL TRIAL IN BRONCHIECTASIS (B305) |
| 24/04/13 | PRICE SENSITIVE | | Share |
|
